Equities research analysts forecast that BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) will report $0.22 earnings per share for the current fiscal quarter, Zacks reports. Ten analysts have provided estimates for BioMarin Pharmaceutical’s earnings. The highest EPS estimate is $0.27 and the lowest is $0.15. BioMarin Pharmaceutical posted earnings of ($0.07) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 414.3%. The firm is scheduled to report its next quarterly earnings results on Thursday, February 20th.
On average, analysts expect that BioMarin Pharmaceutical will report full-year earnings of $0.90 per share for the current fiscal year, with EPS estimates ranging from $0.82 to $0.93. For the next year, analysts forecast that the firm will report earnings of $1.77 per share, with EPS estimates ranging from $1.34 to $2.50. Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover BioMarin Pharmaceutical.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its quarterly earnings data on Wednesday, October 23rd. The biotechnology company reported $0.31 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.25. BioMarin Pharmaceutical had a negative net margin of 2.65% and a negative return on equity of 1.35%. The business had revenue of $461.10 million during the quarter, compared to the consensus estimate of $455.78 million. During the same quarter last year, the firm earned ($0.07) earnings per share. The firm’s quarterly revenue was up 17.7% compared to the same quarter last year.
A number of equities analysts recently issued reports on the company. SunTrust Banks began coverage on BioMarin Pharmaceutical in a report on Tuesday, November 12th. They set a “buy” rating and a $110.00 price objective for the company. Zacks Investment Research lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research note on Wednesday, November 6th. BidaskClub upgraded BioMarin Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. William Blair reissued a “buy” rating on shares of BioMarin Pharmaceutical in a research note on Friday, November 15th. Finally, Canaccord Genuity cut their price target on shares of BioMarin Pharmaceutical from $117.00 to $108.00 and set a “buy” rating on the stock in a report on Monday, October 28th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $107.67.
In other news, EVP George Eric Davis sold 3,190 shares of the business’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $79.66, for a total value of $254,115.40. Following the completion of the sale, the executive vice president now owns 68,709 shares in the company, valued at approximately $5,473,358.94. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director V Bryan Lawlis sold 3,750 shares of the business’s stock in a transaction dated Tuesday, September 17th. The shares were sold at an average price of $74.47, for a total transaction of $279,262.50. Following the completion of the sale, the director now owns 27,340 shares of the company’s stock, valued at approximately $2,036,009.80. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 21,940 shares of company stock valued at $1,657,128. 1.97% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. North Star Investment Management Corp. purchased a new position in BioMarin Pharmaceutical during the third quarter valued at approximately $25,000. Doyle Wealth Management purchased a new stake in BioMarin Pharmaceutical during the second quarter worth $26,000. Usca Ria LLC purchased a new stake in BioMarin Pharmaceutical during the third quarter worth $26,000. Meeder Asset Management Inc. lifted its holdings in BioMarin Pharmaceutical by 73.6% during the third quarter. Meeder Asset Management Inc. now owns 408 shares of the biotechnology company’s stock worth $27,000 after buying an additional 173 shares during the period. Finally, Avestar Capital LLC boosted its position in BioMarin Pharmaceutical by 36.9% during the 2nd quarter. Avestar Capital LLC now owns 750 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 202 shares in the last quarter. Hedge funds and other institutional investors own 95.51% of the company’s stock.
Shares of NASDAQ BMRN traded up $0.53 during midday trading on Thursday, hitting $79.43. The company’s stock had a trading volume of 1,385,245 shares, compared to its average volume of 1,238,281. The company has a current ratio of 3.77, a quick ratio of 2.53 and a debt-to-equity ratio of 0.27. The business’s 50 day moving average is $75.84 and its two-hundred day moving average is $77.21. BioMarin Pharmaceutical has a 12-month low of $62.88 and a 12-month high of $100.13. The firm has a market cap of $14.36 billion, a P/E ratio of -240.70 and a beta of 1.31.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.
Further Reading: Book Value Per Share in Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BioMarin Pharmaceutical Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com’s FREE daily email newsletter.